logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Genentech, Inc. drugs

    FiltersReset Filters
    42 results

    • actemra

      (tocilizumab)
      Genentech, Inc.
      Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome, and COVID-19 in hospitalized adults receiving systemic corticosteroids.

    • activase

      (Alteplase)
      Genentech, Inc.
      Usage: Activase is indicated for the treatment of acute ischemic stroke, acute myocardial infarction (AMI) to reduce mortality and heart failure incidence, and lysis of acute massive pulmonary embolism with significant obstruction or unstable hemodynamics. Treatment should be initiated quickly, particularly for stroke within 3 hours of symptom onset.

    • alecensa

      (ALECTINIB HYDROCHLORIDE)
      Genentech, Inc.
      Usage: ALECENSA is indicated for adjuvant treatment in adults with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adult patients with metastatic ALK-positive NSCLC, both detected by an FDA-approved test.

    • avastin

      (bevacizumab)
      Genentech, Inc.
      Usage: Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

    • cathflo activase

      (Alteplase)
      Genentech, Inc.
      Usage: Cathflo® Activase® (Alteplase) is indicated for restoring function to central venous access devices, specifically to facilitate the withdrawal of blood.

    • cellcept

      (Mycophenolate Mofetil)
      Genentech, Inc.
      Usage: CELLCEPT (mycophenolate mofetil) is indicated for the prevention of organ rejection in adult and pediatric patients (3 months and older) receiving allogeneic kidney, heart, or liver transplants, used alongside other immunosuppressive agents.

    • columvi

      (Glofitamab)
      Genentech, Inc.
      Usage: COLUMVI is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma from follicular lymphoma, following two or more lines of systemic therapy. This indication is granted under accelerated approval, pending further confirmation of clinical benefit.

    • cotellic

      (COBIMETINIB)
      Genentech, Inc.
      Usage: COTELLIC® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with vemurafenib, and as a single agent for adult patients with histiocytic neoplasms.

    • erivedge

      (vismodegib)
      Genentech, Inc.
      Usage: ERIVEDGE is indicated for adults with metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred after surgery, as well as those who are not candidates for surgery or radiation.

    • esbriet - pirfenidone capsule

      (Pirfenidone)
      Genentech, Inc.